Tumor-infiltrating regulatory dendritic cells inhibit CD8+ T cell function via L-arginine metabolism.
暂无分享,去创建一个
P. Allen | M. Cella | L. Norian | P. Rodriguez | A. Ochoa | Paulo C Rodriguez | Augusto C Ochoa | Marina Cella | Paul M Allen | J. Zabaleta | Jovanny Zabaleta | Lyse A Norian | Leigh A O'Mara | L. O’Mara
[1] C. Reis e Sousa. Dendritic cells in a mature age , 2006, Nature reviews. Immunology.
[2] D. Keskin,et al. Potential Regulatory Function of Human Dendritic Cells Expressing Indoleamine 2,3-Dioxygenase , 2002, Science.
[3] D. Quiceno,et al. L-arginine availability regulates T-lymphocyte cell-cycle progression. , 2007, Blood.
[4] J. Ochoa,et al. Regulation of T Cell Receptor CD3ζ Chain Expression byl-Arginine* , 2002, The Journal of Biological Chemistry.
[5] Paolo Serafini,et al. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. , 2006, Seminars in cancer biology.
[6] H. Groux,et al. Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. , 2003, Immunity.
[7] M. Colombo,et al. Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. , 2003, Blood.
[8] David Pozo,et al. Vasoactive intestinal peptide induces regulatory dendritic cells with therapeutic effects on autoimmune disorders. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[9] S. Ostrand-Rosenberg,et al. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. , 1998, Cancer research.
[10] J. Blay,et al. Dendritic Cell Infiltration and Prognosis of Early Stage Breast Cancer , 2004, Clinical Cancer Research.
[11] T. Curiel,et al. Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity , 2003, Nature Medicine.
[12] Weiping Zou,et al. Immunosuppressive networks in the tumour environment and their therapeutic relevance , 2005, Nature Reviews Cancer.
[13] Lu Shi-min,et al. Amino Acid Regulation of Gene Expression , 2006 .
[14] E. Jaffee,et al. Mechanisms of immune evasion by tumors. , 2006, Advances in immunology.
[15] P. Allen,et al. Rapid Maturation of Effector T Cells in Tumors, but Not Lymphoid Organs, during Tumor Regression , 2007, PloS one.
[16] A. Yang,et al. Tumor-induced interleukin 10 suppresses the ability of splenic dendritic cells to stimulate CD4 and CD8 T-cell responses. , 2003, Cancer research.
[17] R. Schreiber,et al. Eradication of established tumors by CD8+ T cell adoptive immunotherapy. , 2000, Immunity.
[18] P. Allen,et al. T Cell-Mediated Delay of Spontaneous Mammary Tumor Onset: Increased Efficacy with In Vivo versus In Vitro Activation1 , 2005, The Journal of Immunology.
[19] P. Kaye,et al. Stromal cells direct local differentiation of regulatory dendritic cells. , 2004, Immunity.
[20] Hua Tang,et al. Splenic stroma drives mature dendritic cells to differentiate into regulatory dendritic cells , 2004, Nature Immunology.
[21] P. Allen,et al. Priming in the Presence of IL-10 Results in Direct Enhancement of CD8+ T Cell Primary Responses and Inhibition of Secondary Responses1 , 2005, The Journal of Immunology.
[22] D. Gabrilovich. Mechanisms and functional significance of tumour-induced dendritic-cell defects , 2004, Nature Reviews Immunology.
[23] D. Munn,et al. Ido expression by dendritic cells: tolerance and tryptophan catabolism , 2004, Nature Reviews Immunology.
[24] V. Bronte,et al. Regulation of immune responses by L-arginine metabolism , 2005, Nature Reviews Immunology.
[25] Lin Zhang,et al. Tumor-infiltrating dendritic cell precursors recruited by a β-defensin contribute to vasculogenesis under the influence of Vegf-A , 2004, Nature Medicine.
[26] A. Sica,et al. Altered macrophage differentiation and immune dysfunction in tumor development. , 2007, The Journal of clinical investigation.
[27] G. Prendergast,et al. Indoleamine 2,3-dioxygenase in immune suppression and cancer. , 2007, Current cancer drug targets.
[28] C. Aspord,et al. Breast cancer instructs dendritic cells to prime interleukin 13–secreting CD4+ T cells that facilitate tumor development , 2007, The Journal of experimental medicine.
[29] M. Colombo,et al. IL-4-Induced Arginase 1 Suppresses Alloreactive T Cells in Tumor-Bearing Mice1 , 2003, The Journal of Immunology.
[30] Piero Musiani,et al. Interleukin 12–mediated Prevention of Spontaneous Mammary Adenocarcinomas in Two Lines of Her-2/neu Transgenic Mice , 1998, The Journal of experimental medicine.
[31] L. Old,et al. Cell surface antigens of chemically induced sarcomas of the mouse. I. Murine leukemia virus-related antigens and alloantigens on cultured fibroblasts and sarcoma cells: description of a unique antigen on BALB/c Meth A sarcoma , 1977, The Journal of experimental medicine.
[32] Katsuaki Sato,et al. Regulatory dendritic cells protect mice from murine acute graft-versus-host disease and leukemia relapse. , 2003, Immunity.
[33] J. Banchereau,et al. In Breast Carcinoma Tissue, Immature Dendritic Cells Reside within the Tumor, Whereas Mature Dendritic Cells Are Located in Peritumoral Areas , 1999, The Journal of experimental medicine.
[34] M. Colombo,et al. The terminology issue for myeloid-derived suppressor cells. , 2007, Cancer research.
[35] J. Connolly,et al. Disruption of E-cadherin-mediated adhesion induces a functionally distinct pathway of dendritic cell maturation. , 2007, Immunity.
[36] P. Allen,et al. Successful elimination of large established tumors and avoidance of antigen-loss variants by aggressive adoptive T cell immunotherapy. , 2003, International immunology.
[37] P. Allen,et al. No Intrinsic Deficiencies in CD8+ T Cell-Mediated Antitumor Immunity with Aging1 , 2004, The Journal of Immunology.
[38] Lloyd J. Old,et al. Adaptive immunity maintains occult cancer in an equilibrium state , 2007, Nature.
[39] Hua Yu,et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity , 2005, Nature Medicine.
[40] C. Chiang,et al. A feedback transcriptional mechanism controls the level of the arginine/lysine transporter cat-1 during amino acid starvation. , 2007, The Biochemical journal.
[41] E. Gilboa. DC-based cancer vaccines. , 2007, The Journal of clinical investigation.
[42] G. Rabinovich,et al. Immunosuppressive strategies that are mediated by tumor cells. , 2007, Annual review of immunology.
[43] J. Brayer,et al. Arginase I Production in the Tumor Microenvironment by Mature Myeloid Cells Inhibits T-Cell Receptor Expression and Antigen-Specific T-Cell Responses , 2004, Cancer Research.
[44] J. Blay,et al. Breast carcinoma cells promote the differentiation of CD34+ progenitors towards 2 different subpopulations of dendritic cells with CD1ahighCD86−Langerin‐ and CD1a+CD86+Langerin+ phenotypes , 2004, International journal of cancer.
[45] R. Offringa,et al. Activation of Dendritic Cells That Cross-Present Tumor-Derived Antigen Licenses CD8+ CTL to Cause Tumor Eradication1 , 2004, The Journal of Immunology.
[46] Craig Murdoch,et al. The role of myeloid cells in the promotion of tumour angiogenesis , 2008, Nature Reviews Cancer.